tiprankstipranks
Amgen (HK:4332)
:4332
Hong Kong Market
4332
Amgen
RESEARCH TOOLSreports

Amgen (4332) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

4332 Analyst Ratings

Moderate Buy
24Ratings
Moderate Buy
12 Buy
11 Hold
1 Sell
Based on 24 analysts giving stock ratings to
Amgen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4332 Stock 12 Month Forecast

Average Price Target

HK$2,867.29
―
Based on 24 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is HK$2,867.29 with a high forecast of HK$3,377.88 and a low forecast of HK$2,306.65. The average price target represents a 1592836.35% change from the last price of HK$0.18.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1685":"HK$1,685","3378":"HK$3,378","2108.25":"HK$2,108.3","2531.5":"HK$2,531.5","2954.75":"HK$2,954.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3377.876472,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$3.38K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2867.28542195,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$2.87K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2306.6517575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$2.31K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1685,2108.25,2531.5,2954.75,3378],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1885.3751132307693,2009.7502264615384,2134.1253396923075,2258.500452923077,2382.875566153846,2507.2506793846155,2631.625792615385,2756.0009058461537,2880.376019076923,3004.7511323076924,3129.1262455384613,3253.501358769231,{"y":3377.876472,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1846.0988786115386,1931.197757223077,2016.2966358346155,2101.395514446154,2186.4943930576924,2271.593271669231,2356.692150280769,2441.7910288923076,2526.889907503846,2611.9887861153848,2697.0876647269233,2782.186543338462,{"y":2867.28542195,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1802.9732121153845,1844.9464242307693,1886.9196363461538,1928.8928484615385,1970.866060576923,2012.8392726923075,2054.8124848076923,2096.785696923077,2138.7589090384613,2180.732121153846,2222.7053332692303,2264.678545384615,{"y":2306.6517575,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1686.776,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1686.776,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1686.776,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1704.781,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1704.781,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1704.781,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1722.976,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1722.976,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1722.976,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.299,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.299,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.299,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1761,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$3,378Average Price TargetHK$2,867Lowest Price TargetHK$2,307
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on HK:4332
David Amsellem
Piper Sandler
Piper Sandler
HK$3,377.88
Buy
1876498.04%
Upside
Reiterated
03/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scotiabank Analyst forecast on HK:4332
Louise Chen
Scotiabank
Scotiabank
HK$3,010.38
Buy
1672331.12%
Upside
Reiterated
03/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Apogee Therapeutics (NASDAQ: APGE) and Gilead Sciences (NASDAQ: GILD)
Bernstein Analyst forecast on HK:4332
Courtney Breen
Bernstein
Bernstein
HK$2,619.42
Hold
1455132.28%
Upside
Reiterated
03/12/26
Bernstein Sticks to Their Hold Rating for Amgen (AMGN)
Barclays Analyst forecast on HK:4332
Emily Field
Barclays
Barclays
HK$2,736.71
Hold
1520291.93%
Upside
Assigned
03/12/26
Barclays Reaffirms Their Hold Rating on Amgen (AMGN)
TD Cowen Analyst forecast on HK:4332
Yaron Werber
TD Cowen
TD Cowen
HK$3,041.65→HK$3,284.05
Buy
1824370.32%
Upside
Reiterated
03/11/26
Jefferies Analyst forecast on HK:4332
Akash Tewari
Jefferies
Jefferies
HK$2,736.71
Hold
1520291.93%
Upside
Initiated
03/10/26
Amgen initiated with a Hold at JefferiesAmgen initiated with a Hold at Jefferies
Truist Financial Analyst forecast on HK:4332
Gregory Renza
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), ANI Pharmaceuticals (NASDAQ: ANIP) and ALX Oncology Holdings (NASDAQ: ALXO)
Wells Fargo Analyst forecast on HK:4332
Mohit Bansal
Wells Fargo
Wells Fargo
HK$2,541.23→HK$2,932.18
Hold
1628891.35%
Upside
Reiterated
02/19/26
Amgen price target raised to $375 from $325 at Wells FargoAmgen price target raised to $375 from $325 at Wells Fargo
Mizuho Securities Analyst forecast on HK:4332
Salim Syed
Mizuho Securities
Mizuho Securities
HK$2,189.36→HK$2,306.65
Hold
1281373.20%
Upside
Reiterated
02/11/26
Amgen price target raised to $295 from $280 at MizuhoAmgen price target raised to $295 from $280 at Mizuho
Argus Research Analyst forecast on HK:4332
Unknown Analyst
Argus Research
Not Ranked
Argus Research
HK$3,127.66
Buy
1737490.78%
Upside
Reiterated
02/06/26
Amgen (AMGN) Receives a Buy from Argus Research
Guggenheim Analyst forecast on HK:4332
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
HK$2,384.84→HK$2,713.25
Hold
1507260.00%
Upside
Reiterated
02/05/26
Guggenheim Remains a Hold on Amgen (AMGN)
Citi Analyst forecast on HK:4332
Geoff Meacham
Citi
Citi
HK$2,463.03→HK$2,697.61
Hold
1498572.05%
Upside
Reiterated
02/04/26
Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating
Morgan Stanley Analyst forecast on HK:4332
Terence Flynn
Morgan Stanley
Morgan Stanley
HK$2,377.02→HK$2,416.12
Hold
1342188.88%
Upside
Reiterated
02/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Caribou Biosciences (NASDAQ: CRBU) and Boston Scientific (NYSE: BSX)
BMO Capital Analyst forecast on HK:4332
Evan Seigerman
BMO Capital
BMO Capital
HK$2,908.73
Buy
1615859.42%
Upside
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)
Goldman Sachs Analyst forecast on HK:4332
Salveen Richter
Goldman Sachs
Goldman Sachs
HK$3,244.95
Buy
1802650.43%
Upside
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Johnson & Johnson (NYSE: JNJ)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on HK:4332
David Amsellem
Piper Sandler
Piper Sandler
HK$3,377.88
Buy
1876498.04%
Upside
Reiterated
03/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scotiabank Analyst forecast on HK:4332
Louise Chen
Scotiabank
Scotiabank
HK$3,010.38
Buy
1672331.12%
Upside
Reiterated
03/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Apogee Therapeutics (NASDAQ: APGE) and Gilead Sciences (NASDAQ: GILD)
Bernstein Analyst forecast on HK:4332
Courtney Breen
Bernstein
Bernstein
HK$2,619.42
Hold
1455132.28%
Upside
Reiterated
03/12/26
Bernstein Sticks to Their Hold Rating for Amgen (AMGN)
Barclays Analyst forecast on HK:4332
Emily Field
Barclays
Barclays
HK$2,736.71
Hold
1520291.93%
Upside
Assigned
03/12/26
Barclays Reaffirms Their Hold Rating on Amgen (AMGN)
TD Cowen Analyst forecast on HK:4332
Yaron Werber
TD Cowen
TD Cowen
HK$3,041.65→HK$3,284.05
Buy
1824370.32%
Upside
Reiterated
03/11/26
Jefferies Analyst forecast on HK:4332
Akash Tewari
Jefferies
Jefferies
HK$2,736.71
Hold
1520291.93%
Upside
Initiated
03/10/26
Amgen initiated with a Hold at JefferiesAmgen initiated with a Hold at Jefferies
Truist Financial Analyst forecast on HK:4332
Gregory Renza
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), ANI Pharmaceuticals (NASDAQ: ANIP) and ALX Oncology Holdings (NASDAQ: ALXO)
Wells Fargo Analyst forecast on HK:4332
Mohit Bansal
Wells Fargo
Wells Fargo
HK$2,541.23→HK$2,932.18
Hold
1628891.35%
Upside
Reiterated
02/19/26
Amgen price target raised to $375 from $325 at Wells FargoAmgen price target raised to $375 from $325 at Wells Fargo
Mizuho Securities Analyst forecast on HK:4332
Salim Syed
Mizuho Securities
Mizuho Securities
HK$2,189.36→HK$2,306.65
Hold
1281373.20%
Upside
Reiterated
02/11/26
Amgen price target raised to $295 from $280 at MizuhoAmgen price target raised to $295 from $280 at Mizuho
Argus Research Analyst forecast on HK:4332
Unknown Analyst
Argus Research
Not Ranked
Argus Research
HK$3,127.66
Buy
1737490.78%
Upside
Reiterated
02/06/26
Amgen (AMGN) Receives a Buy from Argus Research
Guggenheim Analyst forecast on HK:4332
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
HK$2,384.84→HK$2,713.25
Hold
1507260.00%
Upside
Reiterated
02/05/26
Guggenheim Remains a Hold on Amgen (AMGN)
Citi Analyst forecast on HK:4332
Geoff Meacham
Citi
Citi
HK$2,463.03→HK$2,697.61
Hold
1498572.05%
Upside
Reiterated
02/04/26
Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating
Morgan Stanley Analyst forecast on HK:4332
Terence Flynn
Morgan Stanley
Morgan Stanley
HK$2,377.02→HK$2,416.12
Hold
1342188.88%
Upside
Reiterated
02/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Caribou Biosciences (NASDAQ: CRBU) and Boston Scientific (NYSE: BSX)
BMO Capital Analyst forecast on HK:4332
Evan Seigerman
BMO Capital
BMO Capital
HK$2,908.73
Buy
1615859.42%
Upside
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck & Company (NYSE: MRK)
Goldman Sachs Analyst forecast on HK:4332
Salveen Richter
Goldman Sachs
Goldman Sachs
HK$3,244.95
Buy
1802650.43%
Upside
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Johnson & Johnson (NYSE: JNJ)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months
xxx
Success Rate
11/15 ratings generated profit
73%
Average Return
+7.04%
reiterated a xxx
 rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +7.04% per trade.
1 Year
David AmsellemPiper Sandler
Success Rate
14/15 ratings generated profit
93%
Average Return
+21.91%
reiterated a buy rating 5 days ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +21.91% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
100%
Average Return
+28.40%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +28.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4332 Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
0
0
0
0
0
Buy
38
41
41
81
76
Hold
31
21
19
38
39
Sell
2
1
3
2
2
Strong Sell
0
0
0
0
0
total
71
63
63
121
117
In the current month, 4332 has received 76 Buy Ratings, 39 Hold Ratings, and 2 Sell Ratings. 4332 average Analyst price target in the past 3 months is 2,867.29.
Each month's total comprises the sum of three months' worth of ratings.

4332 Financial Forecast

4332 Earnings Forecast

Next quarter’s earnings estimate for 4332 is HK$37.40 with a range of HK$32.66 to HK$48.16. The previous quarter’s EPS was HK$41.43. 4332 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4332 is HK$37.40 with a range of HK$32.66 to HK$48.16. The previous quarter’s EPS was HK$41.43. 4332 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.

4332 Sales Forecast

Next quarter’s sales forecast for 4332 is HK$67.18B with a range of HK$65.17B to HK$72.52B. The previous quarter’s sales results were HK$77.50B. 4332 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.
Next quarter’s sales forecast for 4332 is HK$67.18B with a range of HK$65.17B to HK$72.52B. The previous quarter’s sales results were HK$77.50B. 4332 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.

4332 Stock Forecast FAQ

What is HK:4332’s average 12-month price target, according to analysts?
Based on analyst ratings, Amgen’s 12-month average price target is 2,867.29.
    What is HK:4332’s upside potential, based on the analysts’ average price target?
    Amgen has 1592836.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Amgen a Buy, Sell or Hold?
          Amgen has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 11 hold ratings and 1 sell ratings.
            What is Amgen’s share price target?
            The average share price target for Amgen is 2,867.29. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$3,377.88 ,and the lowest forecast is HK$2,306.65. The average share price target represents 1592836.35% Increase from the current price of HK$0.18.
              What do analysts say about Amgen?
              Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.
                How can I buy shares of Amgen?
                To buy shares of HK:4332, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.